Skip to main content

Journal Club - January 13, 2022


Isabel Kim presented the AVATAR Trial, which is an investigator-initiated international prospective randomized controlled trial that evaluated the safety and efficacy of early SAVR compared to conservative treatment in the treatment of asymptomatic patients with severe AS and normal LV function. The primary outcome was a composite of all-cause death, acute myocardial infarction, stroke or unplanned hospitalization for heart failure. The trial was published in Circulation in November of this year and was presented at AHA in November.

CCI is an inclusive centre with multidisciplinary membership for all cardiovascular investigators in BC